Adam P. Dicker - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Adam P. Dicker's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Adam P. Dicker
Verified
Professor, Thomas Jefferson University, JCO- Clinical Cancer Informatics
Philadelphia
Beats
Content
Multimodal Artificial Intelligence Concordance Between Whole-Mount Specimens and Tissue Microarrays in Prostate Cancer Analysis - Adam Dicker
By Adam P. Dicker| UroToday Verified Read the Full Video TranscriptAlicia Morgans: Hi. I'm so excited to be here today, talking with Dr. Adam Dicker at GU ASCO 2025. He's joining me from Thomas Jefferson University. Thank you so much for being here. Adam P. Dicker: My pleasure. Alicia Morgans: Wonderful. So there's been a lot of excitement about MMAI, this artificial intelligence that helps us really understand pathology specimens on a deeper level, maybe being prognostic or predictive of certain outcomes for patients.
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma | Journal of Clinical Oncology
By Christina Tsien, Stephanie Pugh, Adam P. Dicker, Jeffrey J. Raizer| ascopubs.org@ Article Tools ORIGINAL REPORTS Neurooncology Abstract Full Text PDF Figures and Tables Supplements AbstractTo assess whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS), compared with BEV alone in recurrent glioblastoma (GBM).
Multimodal Artificial Intelligence Concordance Between Whole-Mount Specimens and Tissue Microarrays in Prostate Cancer Analysis - Adam Dicker
By Adam P. Dicker| UroToday Verified Read the Full Video TranscriptAlicia Morgans: Hi. I'm so excited to be here today, talking with Dr. Adam Dicker at GU ASCO 2025. He's joining me from Thomas Jefferson University. Thank you so much for being here. Adam P. Dicker: My pleasure. Alicia Morgans: Wonderful. So there's been a lot of excitement about MMAI, this artificial intelligence that helps us really understand pathology specimens on a deeper level, maybe being prognostic or predictive of certain outcomes for patients.
Company Info
JCO- Clinical Cancer Informatics
Philadelphia, Pennsylvania, United States
+1 215-503-8890